John Burke, MD | Authors

John Burke, MD, Discuses the Key Findings of the KEYNOTE-564 Trial With Pembrolizumab in High-Risk RCC

November 17, 2021

CancerNetwork®sat down with John Burke, MD, to talk about the topline results in the KEYNOTE-564 trial, which examined the use of pembrolizumab in a population of patients with high-risk renal cell carcinoma.

John Burke, MD, Discuses the Rationale for Examining Pembrolizumab in High-Risk RCC After Surgery

November 16, 2021

CancerNetwork®sat down with John Burke, MD, to discuss why treatment with pembrolizumab post-surgery may be a promising option for patients with high-risk renal cell carcinoma.